Liquid biopsy company Grail raised $390m in a fourth round of financing, bringing the total funding to $1.9bn.
Liquid biopsy company Grail Inc. announced today it has raised $390m in a series D financing round from new investors Public Sector Pension Investment Board and Canada Pension Plan Investment Board and existing backers – including Illumina Inc. – to advance its cancer-detecting blood test. This brings Grail’s total funding raised to $1.9bn.
This funding comes just weeks after the Menlo Park, CA-based liquid biopsy company announced study results from almost 6,700 participants....
Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.
CEO Alexandre Chau told Medtech Insight that the Middle East and Africa presented the ideal mix of market potential, physician training opportunities, and regulatory readiness when the company was considering expansion markets beyond Europe and the US.
A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.
Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.
Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.
The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.
CEO Alexandre Chau told Medtech Insight that the Middle East and Africa presented the ideal mix of market potential, physician training opportunities, and regulatory readiness when the company was considering expansion markets beyond Europe and the US.
